NASDAQ:APRE

Aprea Therapeutics Q2 2026 Earnings Results & Report

Aprea Therapeutics logo
$0.45 +0.05 (+11.52%)
Closing price 04:00 PM Eastern
Extended Trading
$0.45 0.00 (-0.46%)
As of 06:18 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Aprea Therapeutics beat analyst earnings expectations in its Q2 2026 results, released August 12, 2026. The company reported EPS of -$0.07 versus the -$0.1775 consensus estimate.

Earnings Announcement Details

Quarter
Q2 2026
Report Date
Time
Before Market Opens
Conference Call
8:30 AM ET

Aprea Therapeutics EPS Results

Actual EPS
-$0.07
Consensus EPS
-$0.1775
Beat/Miss
Beat by +$0.1075
One Year Ago EPS
N/A
EPS Beat Rate
5 of last 8 quarters

Aprea Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
$253 thousand
Beat/Miss
N/A
YoY Revenue Growth
N/A

Aprea Therapeutics Q2 2026 Earnings FAQ

Aprea Therapeutics (NASDAQ:APRE) reported earnings of -$0.07 per share for Q2 2026, beating the consensus estimate of -$0.1775. The report was announced on Wednesday, August 12, 2026.

Aprea Therapeutics Earnings Headlines

Today's free pick (on me)
Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one lesser known company. With plans filed for 1,000,000 new satellites, that licensing fee could scale dramatically. Analyst Dylan says the stock could move by December 8th.tc pixel
See More Aprea Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Aprea Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aprea Therapeutics and other key companies, straight to your email.

About Aprea Therapeutics

Aprea Therapeutics (NASDAQ:APRE) is a clinical-stage biotechnology company focused on developing investigational cancer treatments. Its research centers on the DNA damage response, a network of cellular processes that helps repair damaged DNA and that can be targeted in some cancers.

The company’s pipeline has included ATR inhibitors, a class of experimental medicines intended to disrupt cancer cells’ ability to respond to DNA damage. Aprea has evaluated these candidates in early-stage clinical research; they are investigational and have not been established as approved treatments.

View Aprea Therapeutics Profile